Studying elite responders can reveal protective antibodies that help the rest of us fight disease.

Source thesis

DCVC describes Alchemab's approach of studying unusually resilient people to identify potentially protective antibodies and develop therapeutic candidates. The opportunity is discovery grounded in exceptional immune responses, not a general promise that transferring such responses will prevent disease.